SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that Roche has received approval from Health Canada for a subcutaneous (SC)
formulation of trastuzumab (Herceptin SC) for the treatment of patients with HER2-positive breast cancer. This is a
co-formulation with Halozyme's proprietary recombinant human hyaluronidase enzyme (ENHANZE® technology).
"We are pleased that the subcutaneous formulation of trastuzumab (Herceptin SC) has been approved in Canada," said Dr. Helen Torley, president and chief executive officer.
"Patients and health care providers will now have another treatment option with the potential for a reduced administration
time."
The U.S. Food and Drug Administration accepted a Biologics License Application from Genentech for a subcutaneous (SC)
formulation of trastuzumab (Herceptin SC) in July 2018.
About ENHANZE® Technology
Halozyme's proprietary ENHANZE® drug-delivery technology is based on its patented recombinant human
hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be
delivered subcutaneously (just under the skin). By using rHuPH20, some biologics and compounds that are administered
intravenously may instead be delivered subcutaneously. ENHANZE may also benefit subcutaneous biologics by reducing the need for
multiple injections. This delivery has been shown in studies to reduce health care practitioner time required for administration
and shorten time for drug administration.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies
that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa
(PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug
therapies to the tumor in animal models. PEGPH20 is currently in development for the treatment of several cancers and has the
potential to be used in combination with different types of cancer therapies. In addition to its proprietary product portfolio,
Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer,
Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion for its ENHANZE® drug delivery technology. Halozyme is
headquartered in San Diego. For more information visit www.halozyme.com.
Halozyme Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including,
without limitation, statements concerning the Company's future expectations and plans for growth in 2018, entering into new
collaboration agreements, the development and commercialization of product candidates, including timing of clinical trial results
announcements and future development and commercial activities of our collaboration partners, the potential benefits and
attributes of such product candidates and expected financial outlook for 2018) that involve risk and uncertainties that could
cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are
typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends,"
"estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of
similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result
of several factors, including unexpected expenditures and costs, unexpected fluctuations or changes in revenues, including
revenues from collaborators, unexpected delays in entering into new collaboration agreements, unexpected results or delays in
development of product candidates, including delays in clinical trial patient enrollment and development activities of our
collaboration partners, and regulatory review, regulatory approval requirements, unexpected adverse events and competitive
conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly
Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2018.
Contacts:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
858-356-5932
robert.uhl@westwicke.com
Laurie Stelzer
858-704-8222
ir@halozyme.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/halozyme-announces-approval-of-subcutaneous-formulation-of-trastuzumab-herceptin-in-canada-300713267.html
SOURCE Halozyme Therapeutics, Inc.